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Mortality among the patients with chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) remains high because of the very high incidence of cardiovascular 
disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. 
Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early 
diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for 
the better management to identify and utilize cardiovascular (CV) biomarkers in profiling 
CVD risk and enabling stratification of early mortality. This review summarizes current 
evidence about renocardiovascular biomarkers: CV biomarkers in patients with CKD as 
well as with ESRD, emphasizing on the emerging biomarkers: B-type natriuretic peptide, 
cardiac troponins, copeptin, the biomarker of renal injury (neutrophil gelatinase-associ-
ated lipocalin), and the mineral and bone disorder hormone/marker (fibroblast growth 
factor-23). Furthermore, it discusses their potential roles especially in ESRD and in future 
diagnostic and therapeutic strategies for CVD in the context of managing cardiorenal 
syndrome.
Keywords: biomarker, cardiovascular disease, cardiorenal syndrome, chronic kidney disease, end-stage renal 
disease
CARDiOvASCULAR (Cv) DiSeASeS iN CHRONiC KiDNeY 
DiSeASe (CKD)/eND-STAGe ReNAL DiSeASe (eSRD)
Chronic kidney disease is frequently associated with a progressive decrease in glomerular filtration 
rate (GFR), which leads to ESRD. The number of patients with CKD as well as ESRD is increasing 
markedly worldwide, with poor outcomes and high cost. Cardiovascular disease (CVD) is closely 
associated with CKD and ESRD and is well shown as the leading cause of morbidity and mortality in 
the patients with CKD, most notably those on ESRD or dialysis (1). The prevalence of concomitant 
coronary artery disease (CAD), left ventricular hypertrophy (LVH), congestive heart failure (CHF), 
cardiac arrhythmia (most commonly atrial fibrillation), and valvular/vascular calcification are 
increased in CKD patients. Recently, the term, cardiorenal syndrome (CRS) has been introduced 
in an attempt to emphasize the interaction between the CV and renal systems in acute or chronic 
disease setting (2). CRS is a pathophysiological condition in which combined cardiac and renal 
dysfunction amplifies the progression of failure of the individual organs and has an extremely bad 
TABLe 1 | Potential renocardiovascular biomarkers.
Biomarkers Reference
(i) Neurohormones
Natriuretic peptides (ANP, B-type natriuretic 
peptide (BNP), CNP, and related peptides)
BNP and its amino-terminal fragment (NT-proBNP) have become established as the most ideal markers of 
HF so far available
(4)
Endothelin and C-terminal-pro-endothelin-1 
(CT-proET-1)
CT-proET-1 increases in CKD and may be potentially useful biomarkers of renal injury (5)
Arginine vasopressin (AVP) and copeptin Copeptin which is released with AVP, emerges to be a more reliable marker for HF and is also released 
into the circulation early after MI onset and may aid in rapid diagnosis
(6, 7)
Adrenomedullin (ADM) and mid-regional 
proadrenomedullin (MR-proADM)
MR-proADM, which is relatively more stable than ADM, is used to explore the prognostic power for HF 
related deaths, suggesting better predictability than the natriuretic peptides
(8, 9)
(ii) Metabolic hormones/peptides
Triiodothyronine, adrenocorticotropic hormone 
and cortisol
Hormonal derangements at the level of the hypothalamic-pituitary axis are often seen with the CKD or 
CVD
(10)
Adiponectin Although hyperadiponectinemia is a common phenomenon in CKD and is considered to have similar 
beneficial effects on metabolic risk in this patient group, many recent studies have unexpectedly shown 
that high, rather than low, concentrations predict mortality
(11)
Leptin Hyperleptinemia, frequently observed in CKD patients, may play a key role in the pathogenesis of 
complications associated with CKD such as cachexia, protein energy wasting, chronic inflammation, 
insulin resistance, cardiovascular (CV) damages, and bone complications. Leptin may be also involved in 
the progression of renal disease through its pro-fibrotic and pro-hypertensive actions
(12, 13)
(iii) Cardiac injury markers
Cardiac troponins (cTns) There are accumulating evidences of the usefulness of cTns in conditions other than ACS, including HF (14)
Heart-type fatty acid-binding protein (H-FABP) H-FABP as well as cTns is influenced by renal function and the utilities may be somewhat limited in CKD 
patients
(15)
(iv) Oxidative stress markers
Malondialdehyde, 8-hydroxy-2′ 
-deoxyguanosine, oxidized low-density 
lipoproteins
A number of biological markers of oxidative stress have been evaluated for CVD as well as CKD, since 
oxidative stress is a common mediator in pathophysiology of risk factors for the both diseases
(16)
Uric acid Although at present, there are no definite data whether uric acid is causal, compensatory, coincidental, 
or it is only an epiphenomenon in CKD patients, hyperuricemia may contribute to the development and 
progression of CKD and also be linked to CVD
(17, 18)
Advanced glycation endproduct (AGE) Chronic overstimulation of the AGE-receptor for AGE pathway is likely one of major contributors involved 
in the pathophysiology of CVD in patients with CKD
(19)
Asymmetric dimethylarginine (ADMA) ADMA level is a marker and mediator of oxidative stress as well as endothelial dysfunction/atherosclerosis. 
It is accumulated in plasma during CKD and a strong predictor for the progression of CKD and CVD in 
CKD patients. Also in patients with HD, plasma ADMA is a strong and independent predictor of overall 
mortality and CV outcome
(20, 21)
(Continued )
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prognosis. It is more than simultaneous cardiac and renal disease. 
It is now necessary for us to expand our knowledge regarding its 
pathogenesis, prevention, and potential treatment.
ReNOCARDiOvASCULAR BiOMARKeRS
A number of biomarkers have been evaluated in CVD or CKD/
ESRD, and biomarkers pertinent to the CV and renal interface are 
defined as renocardiovascular biomarkers (3). From the perspec-
tive of pathophysiology, they are classified into (I) neurohormones 
(4–9), (II) metabolic hormones/peptides (10–13), (III) cardiac 
injury markers (14, 15), (IV) oxidative stress markers (16–21), 
(V) matrix-related markers (22–27), (VI) inflammatory markers 
(28–31), (VII) renal markers (32), and (VIII) mineral and bone 
disorder hormones/markers (33–41), as summarized in Table 1.
eMeRGiNG ReNOCARDiOvASCULAR 
BiOMARKeRS
Among the biomarkers listed in Table 1, the critical biomarkers in 
the context of managing CRS are discussed in detail, first briefly 
describing their pathological associations and then the evidence 
for their usefulness in relation to important clinical endpoints 
(Figure 1).
A: B-Type Natriuretic Peptide (BNP) and its 
Amino-Terminal Fragment (NT-proBNP)
Upon ventricular myocyte stretch, preproBNP is enzymatically 
cleaved to proBNP and released in the form of the active hormone 
BNP (amino acids 79–108) or an inactive fragment, NT-proBNP 
(amino acids 1–76, released in a1:1 ratio). The hemodynamic 
FiGURe 1 | interrelationships and pivotal roles of the five emerging biomarkers in cardiorenal syndrome. AVP, arginine vasopressin; BNPs, B-type 
natriuretic peptides (BNP and NT-proBNP), CKD, chronic kidney disease; cTns, cardiac troponins (troponin I and T); CVD, cardiovascular disease; ESRD, end-stage 
renal disease; FGF-23, fibroblast growth factor-23; and NGAL, neutrophil gelatinase-associated lipocalin.
Biomarkers Reference
(v) Matrix-related markers
Matrix metalloproteinases and tissue inhibitors 
of MMPs
They have been increasingly linked to both normal physiology and abnormal pathology in the kidney as 
well as heart. However, their roles in the pathophysiology of CRS are extremely complex
(22)
Galectin-3 Galectin-3 has been associated with increased risk for morbidity and mortality in patients with HF. Also, it 
may be causally involved in mechanisms of tubulointerstitial fibrosis and CKD progression
(23–25)
ST2 ST2 is reflective of fibrosis and cardiac remodeling and strongly related to HF outcomes. Also, cross-
sectionally, higher ST2 concentrations appear to be associated with worse kidney function in patients with 
CVD
(26, 27)
(vi) inflammatory markers
High-sensitive C-reactive protein (hs-CRP), 
cytokines and related receptors [Interleukin 
(IL)-1, -2, -6, -8, -18, TNF-α]
Among CKD patients, inflammatory biomarkers including hs-CRP and IL-6 correlate with known CVD and 
provide prognostic information, which suggests inflammation and oxidative stress may contribute to CV 
risk in CKD patients
(28)
Pentraxin-3 (PTX3) Elevated systemic PTX3 levels appear to be a powerful marker of inflammatory status and a superior 
outcome predictor in patients with CKD. It may also provide more information on development and 
progression of atherosclerosis than other less specific markers such as CRP
(29)
Growth differentiation factor-15 (GDF-15) Measurement of circulating GDF-15 provides incremental improvement in mortality risk prediction in 
addition to traditional risk factors as well as cTns and BNP in healthy individuals as well in patients with 
a spectrum of CVD including AMI and HF. Higher circulating GDF-15 is associated with incident renal 
outcomes and improves risk prediction of incident CKD
(30, 31)
(vii) Renal markers
Neutrophil gelatinase-associated lipocalin 
(NGAL), kidney injury molecule-1, liver-type 
fatty acid-binding protein, cystatin C
In AKI and CKD, these renal biomarkers have become useful for assessment and prognostication both in 
plasma and in urine. They are expected to be useful in early diagnosis of renal involvement in CVD such as 
HF, and contrast nephropathy, and to suggest the timing of treatment initiation and its likely effectiveness
(32)
(viii) Mineral and bone disorder hormones/markers
Vitamin D/parathyroid hormone (PTH) Serum markers such as calcium, phosphate, vitamin D and PTH are already in use in clinical practice, and 
increased calcium, increased phosphate, decreased (active) vitamin D, or increased PTH are reported to 
be associated with CVD in CKD/ESRD patients by epidemiologic data. However, the relationship between 
these markers and CVD in CKD patients is complex and may lack causality
(33–37)
Osteoprotegerin (OPG) Elevated OPG levels have been associated with aortic stiffness and markers of CV dysfunction such as 
raised serum troponin T levels
(38)
Fetuin-A Decreased fetuin-A levels are observed in CKD patients, especially in ESRD and are associated with the 
development of vascular calcification
(39)
Fibroblast growth factor-23 (FGF-23) FGF-23 levels among CKD patients are higher than in the general population and are further elevated in 
the dialysis population. It may cause not only rapid progression of renal functional decline, but also the 
development of LVH and HF
(40, 41)
ACS, acute coronary syndromes; AKI, acute kidney injury; CKD, chronic kidney disease; CRS, cardio-renal syndrome; CVD, cardiovascular disease; ESRD, end-stage renal disease; 
HD, hemodialysis; HF, heart failure; LVH, left ventricular hypertrophy; MI, myocardial infarction.
TABLe 1 | Continued
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load (i.e., myocardial stretch) is the most important stimulus 
for BNP and NT-proBNP secretion, based on the results of both 
basic and clinical studies. Iwanaga et al. have demonstrated an 
excellent correlation between BNP and LV end-diastolic wall 
stress (EDWS) (r2 = 0.89, P < 0.001) in HF patients with nor-
mal creatinine levels, and they found that this relationship was 
more robust than any other parameter previously reported (42). 
Currently, both BNP and NT-proBNP are widely used as markers 
for a variety of CVD. However, there are differences between the 
two assays; NT-proBNP has a longer half-life and thus, its levels 
may be more stable (less sensitive to acute stress). In addition, 
NT-proBNP might be more dependent on renal clearance than 
BNP. To date, most studies have demonstrated that both are 
equally useful for diagnosis, management and prognosis, even in 
CKD and hemodialysis (HD) patients.
BNP/NT-proBNP vs. Renal Function
The relationship between BNP/NT-proBNP levels and renal 
dysfunction is complex. Any change in value may be influenced 
by renal dysfunction due to change in clearance. When renal 
dysfunction causes cardiac damage/stress, directly or indirectly, 
this will cause increased BNP/NT-proBNP values. It remains 
unclear whether, in patients with CKD and ESRD, increased 
plasma BNP levels might be due to more hemodynamic stimuli 
or might result from other factors such as anemia, obesity, 
and cachexia or impaired renal clearance of natriuretic pep-
tide, despite similar hemodynamic stimuli. Multiple studies 
have shown an inverse moderate, but significant, correlation 
between estimated glomerular filtration ratio (eGFR) and BNP 
or NT-proBNP concentrations. Niizuma et  al. have recently 
shown that renal dysfunction (reduced eGFR) may contribute 
to increased BNP levels (inverse correlation) independent of 
EDWS (a critical hemodynamic determinant of BNP), anemia, 
HF type, and BMI in a wide spectrum of HF patients with both 
CKD and ESRD (43). Some reports suggest that NT-proBNP is 
more strongly influenced with the severity of renal dysfunction 
than BNP, whereas others show that they are equally dependent 
on the renal function for their clearance. van Kimmenade et al. 
showed BNP and NT-proBNP had nearly identical correlations 
to eGFR (r = −0.35 and r = −0.3, respectively; P < 0.001 for both) 
in 165 hypertensive subjects (44). They went a step further by 
measuring renal fractional extraction (FE) [(renal artery concen-
tration − renal vein concentration)/renal artery concentration] 
of these NPs and found that, across a range of eGFR as low as 
9 mL/min/1.73 m2, FE for BNP and NT-proBNP diminished only 
modestly and correlated minimally with eGFR (r = 0.20–0.26). 
Furthermore, they found in a multivariate regression analysis 
that cardio-related factors such as blood pressure, LV mass, 
and eGFR, but not FE, were significantly associated with NPs 
concentrations.
BNP and NT-proBNP Elevations in ESRD
Among patients with HD or peritoneal dialysis (PD), considerable 
heterogeneity in BNP and NT-proBNP levels has been recognized 
and seems to increase exponentially, which may have caused some 
confusion in interpreting results. In ESRD or dialysis patients, the 
question of whether increased plasma NP levels are due to cardiac 
hemodynamic stimuli, accompanying comorbidities or impaired 
renal clearance of NPs is also a matter of controversy. Recent 
reports in ESRD patients suggest that the NT-proBNP/BNP ratio 
increases even further in patients receiving HD (45). In dialysis 
patients, the parameters related to the dialysis treatment itself 
may influence BNP and NT-proBNP concentrations, like the 
type of dialysis membrane and a patient’s volume status or change 
(46, 47). Certainly, the very high prevalence of LV structural and 
functional abnormalities in ESRD patients may account for the 
remarkable elevations. Zoccali et  al. demonstrated that ANP/
BNP levels were only slightly elevated in dialysis patients who had 
normal cardiac function and no LVH on echocardiography (48).
Diagnostic and Prognostic Utility of BNP and NT-
proBNP in ESRD
The best cut-off values for detecting HF may need to be raised 
when the eGFR is less than 60 mL/min. It should be noted that 
the diagnostic accuracy of plasma BNP and NT-proBNP for HF 
is reduced in this setting, and natriuretic peptide testing for HF 
should be discouraged in patients especially on dialysis. Recently, 
Mishra et al. reported in the large CKD cohort without HF that 
NT-proBNP had strong associations with prevalent LVH and 
LV systolic dysfunction (49). Also, some studies demonstrated 
a close association between BNP or NT-proBNP levels and LV 
mass and systolic function in the ESRD population. Experimental 
studies suggested myocardial ischemia apart from an increased 
mechanical stress, upregulated BNP gene expression, and release 
from ventricular myocardium (50). Recently, Niizuma et al. used 
CAG for a thorough evaluation of disease severity and assessed 
the relationship between BNP and CAD in 125 patients with 
long-term HD (51). Plasma BNP levels showed a predictive value 
for CAD and were closely correlated with disease severity, and 
similar findings were observed also in the studies of patients 
with CKD. Thus, the measurement of plasma BNP levels in 
combination with other non-invasive investigations might help in 
assessing CAD involvement and aggressive management in this 
high-risk population. In addition to their roles in detecting LV 
abnormality or ischemic status, a number of studies suggest BNP 
testing as promising cardiac biomarkers for mortality prediction 
and CV risk stratification also in dialysis patients (48). The larg-
est study by Apple et  al. examined the predialysis NT-proBNP 
levels in 399 HD patients and showed that NT-proBNP was 
significantly predictive of mortality, and the area under the 
receiver operating characteristic curve in relation to mortality 
was higher with NT-proBNP than with cTnT or High-sensitive 
C-reactive protein (52). Also in the largest study in the PD 
population, patients in the highest quartile of NT-proBNP had 
significantly greater risk of mortality, CV death, and events after 
a median follow-up of 36 months (53). All of these data suggest 
the prognostic importance of BNP or NT-proBNP level at a single 
time point, irrespective of whether the measurement was taken 
before dialysis, after dialysis, or midweek between dialysis. In 
addition to CV outcomes, several studies suggested that increased 
BNP and NT-proBNP concentrations were associated with an 
increased risk for accelerated progression of CKD to ESRD (54). 
The mechanism may be complex and cardiac abnormalities or 
other comorbidities in addition to the decreased clearance may 
5Niizuma et al. Biomarkers in Cardiorenal Syndrome
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 10
attribute to the results. In any case, it strongly suggests a dynamic 
interplay between the heart and the kidney as CRS.
B: Troponins
After myocardial cell damage, cardiac troponin (cTn) T and I are 
released from the myocytes and their levels are detectable 3–12 h 
after the injury and mean time to peak cTn level is approximately 
12–48  h. The concentration returns to the normal range after 
5–14 days, which is four times longer than for the creatine kinase 
myocardial band isoenzyme (CK-MB) fraction. The increasing 
sensitivity of cTn assays has had a dramatic impact on the use of 
cTn testing, which is now an essential component of the diagnos-
tic workup and management of acute coronary syndromes (ACS). 
More importantly, the test has prognostic value because it identi-
fies ACS patients who are at substantially increased risk of death 
or recurrent MI (15). Also, the elevated cTn in asymptomatic 
individuals in the community is associated with a tripling of risk 
of all-cause and CV mortality as shown by a recent systematic 
review (55).
cTns in CKD/ESRD
Elevated cTns may be detected in conditions other than ACS, 
including HF, cardiomyopathies, myocarditis, tachyarrhythmia, 
and pulmonary embolism, and even after strenuous exercise in 
healthy individuals (14). Levels of cTns are frequently elevated 
in the absence of ACS among patients with renal dysfunction, 
specifically in 30–75% of ESRD patients. In general, the use of 
more sensitive cTn assays likely shows that the presence of cTn 
elevations in ESRD patients might be even more frequent than 
previously thought. Jacobs et  al. found that by using a more 
sensitive cTnT assay, 94% of patients had cTnT elevations above 
the 99th percentile (56). At one time, it was considered that an 
elevation of the cTns in a setting of decreased creatinine clear-
ance was not of substantial diagnostic or prognostic importance. 
However, the GUSTO IV trial, which included 7,033 patients 
with suspected ACS, indicated that an elevated cTnT level was 
strongly predictive of poor short-term prognosis, regardless of 
creatinine clearance (57). Although the important limitations 
were the very small number of patients with severe CKD or ESRD 
and its confinement to symptomatic patients, cTnT elevation had 
even greater prognostic importance among patients with a mild 
to moderate degree of CKD. Stacy et al. have showed that cTns can 
identify those with a poor prognosis in patients with CKD and 
suspected ACS by a systemic review (58). In addition, they found 
that cTns levels can be helpful but that their diagnostic utility 
is limited by varying estimates of sensitivity and specificity. In 
the clinical setting, serial measurements should be performed in 
patients CKD and suspected ACS because an exact cut-off point 
cannot yet be specified. Moreover, over the past decade, data 
have emerged to suggest that elevated levels of cTns may predict 
death among ESRD patients without symptoms of ACS. A recent 
research by Michos and colleagues have reviewed 98 studies sys-
tematically and showed the association of elevated cTns with worse 
prognosis in CKD patients (receiving or not receiving dialysis) 
without suspected ACS (59). Although the precise mechanism 
of death is unknown, several studies suggest that the prevalence 
of increased levels of cTns may correlate with increased risk of 
CAD. deFillippi et al. found that a high level (>median) vs. a low 
level of cTnT remained an independent predictor of multivessel 
disease (prevalence ratio, 3.7 fold) after adjustment for age and 
history of clinical CAD in stable patients undergoing long-term 
HD (60). They also suggested the potential complementary role 
of serum CRP, which is elevated in more than 70% of HD patients, 
for predicting all-cause mortality. Routine measurement of cTns 
may be prognostically valuable and may help frame therapeutic 
decisions. However, the pathophysiologic mechanisms causing 
random increases in cTn concentrations in patients with renal 
dysfunction or dialysis are still unclear. Elevation of cTn levels in 
ESRD patients is unlikely to be the result of decreased clearance by 
the failing kidney, and cTn elevation might reflect cardiac damage 
in non-ischemic cardiomyopathy or microvascular disease in the 
setting of LV hypertrophy. There is also an evidence that dialysis 
can affect cTn levels (cTnT is increased after HD, whereas cTnI 
is decreased). It should be noted again that cTn testing does not 
provide any insight into the mechanism of cardiac injury and that 
a broad differential diagnosis including renal failure, pulmonary 
embolism and HF is routinely considered when cTn concentra-
tion is elevated in the absence of ACS. In the recent guideline (61), 
measurement of cTns is recommended for the evaluation of ACS 
in patients with ESRD (level of evidence A). A dynamic change 
in cTns of ≥20% after presentation should be used to define ACS 
(level of evidence B). Baseline cTns can aid in defining mortality 
and CV risk for patients with ESRD and provide baseline levels 
for the subsequent comparison (level of evidence B).
cTns in HF
In the context of HF, evidence for a role of cTns continues to 
accumulate, particularly for use in risk stratification. Evidence 
of myocyte cell death in human myocardium has been suggested 
by histologic information of biopsies and more recently by the 
measurement of the serum cTns, which may be able to identify 
subclinical injury to the myocardium. Not only in ischemic HF 
but also in non-ischemic HF, cTns could identify a subgroup of 
patients with severe HF. In patients with acute decompensated 
HF, 6.2% were positive for cTn testing and they showed higher 
in-hospital mortality than those with negative test (62). During 
routine clinical follow-up of ambulatory patients, elevations in 
cTns, particularly frequently or persistently, could be associated 
with an increased risk of events. In addition, Sundström et  al. 
reported that the elevated serum level of cTnI was an independ-
ent contributor to the development of HF in a community-based 
sample of 1,089 70-year-old men (63). Clinical significance of 
increased cTns concentrations in CKD patients with HF as well 
as those with ACS or stable CAD is unclear. Chen et al. reported 
the association of an elevated cTnI with HF in 293 non-ACS 
patients with CKD, where Stage 5 CKD did not modify it (64). 
Bansal et al. reported that cTnT level was strongly associated with 
incident HF in a prospective cohort of 3,483 people with mild 
to severe CKD (65). They also showed not only cTnT but also 
NT-proBNP was independently associated with HF. In patients 
with dialysis, elevated cTnT may be a more important risk factor 
than LV systolic dysfunction alone and adds value when used in 
combination with LV mass index and ejection fraction in predict-
ing circulatory congestion. Recently, Tsutamoto et  al. reported 
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that decreased clearance via the kidney might contribute to the 
elevated cTnT in HF patients with CKD by measuring the dif-
ference of TnT concentration between coronary sinus and aortic 
root (66). However, it is a controversial issue and further large 
studies will be needed to clarify whether renal dysfunction itself or 
additional myocyte damage might impact the clinical outcome in 
HF patients with CKD in the context of CRS. Interestingly, recent 
studies suggest that cTnT and NT-proBNP levels independently 
predicted ESRD risk in the general population or patients with 
diabetic nephropathy and anemia (67). These results may sup-
port a link between cardiac injury and the development of ESRD. 
To date, the data support the concept that structural markers 
of  myocardial damage or strain are perhaps the best prognostic 
markers in high-risk patients with CVD.
C: Copeptin
The effects of arginine vasopressin (AVP) are mediated by 
three receptor types: V1aR, V1bR, and V2R. V1aR-dependent 
vasoconstriction that increases afterload, ventricular stress, and 
cardiac hypertrophy may result in systemic vascular resistance 
and a decrease in cardiac output and contractility while V2R 
is the receptor that governs water retention by activating the 
aquaporin-2 channel on the apical plasma membrane of the 
collecting duct cells (6). Despite its suggested importance in the 
pathogenesis of CVD, the evaluation of AVP secretion has been 
difficult because of the considerable technical issues related to 
AVP measurement and AVP’s short plasma half-life or instability 
(68). Copeptin, a glycosylated 39-amino acid long peptide, is 
the C-terminal part of pro-AVP and is cosecreted in equimolar 
amounts with together with AVP during precursor processing 
(7). In contrast to AVP, copeptin has a longer plasma half-life, is 
very stable at room temperature and easy and robust to measure. 
Studies in healthy subjects have shown plasma copeptin and AVP 
concentrations to correlate strongly over a wide range of osmo-
lality. For these reasons, copeptin is now considered as a robust 
surrogate for AVP, overcoming the technical problems related to 
AVP dosage.
During the last few years, plasma copeptin concentration has 
been measured in a number of clinical investigations. Significant 
associations have been found between baseline copeptin level and 
the incidence or progression of various pathological situations 
such as HF, diabetes, and CKD, suggesting that AVP may play 
causal roles. Other studies have shown that plasma copeptin may 
be a useful diagnostic marker in patients with AMI, sepsis, or 
unexplained hyponatremia. Furthermore, the prognostic values 
of copeptin have already been shown in patients with HF, CAD, 
and with acute stroke. It should be noted that most findings as 
the diagnostic and prognostic marker of CVD were from subjects 
without renal dysfunction.
Copeptin in CKD/ESRD
In CKD, a few data exist evaluating copeptin concentrations, 
which found copeptin to be associated with renal function (69). 
It might be because AVP causes renal function decline, subjects 
with low renal function are less sensitive to the actions of AVP 
or increased copeptin may result from reduced renal elimina-
tion. Increased AVP concentrations in CKD have already been 
reported and are associated with biologic activity. A number of 
contributive factors such as LV dysfunction (or HF), endothelial 
stress, V2 receptor resistance, and diabetes might be related with 
its elevation. However, a recent study in a normal population 
showed that the close relationship between copeptin and AVP 
was distorted in CKD, suggesting that the peptide clearances 
might differ when the renal function is impaired (70). It is 
not conclusive and further studies are necessary. Meijer et  al. 
examined the role of copeptin baseline values and the change 
in renal function in a cohort of 548 renal transplant recipients 
(71). Elevated copeptin concentration was associated with 
an accelerated renal function decline in patients with renal 
transplant, as seen by a decrease in GFR during a median 
follow-up of 3.6 years. A recent cross-sectional study describes 
the association of plasma copeptin levels with eGFR, urinary 
albumin excretion, kidney length, and renal simple cysts in a 
large, multicentric population-based cohort (72). There are a few 
studies investigating associations between plasma copeptin and 
CVD in CKD/ESRD. Fenske et al. have reported an increased 
incidence of CV events in a subgroup of ESRD patients who had 
elevated levels of copeptin (73), and Engelbertz et  al. showed 
elevated copeptin as a prognostic factor, independent of serum 
creatinine (SCr) in patients with both CAD and CKD (74). 
Whether increased AVP (copeptin) secretion is prognostic or 
causative for CVD especially in CKD patients and copeptin may 
serve as a biomarker to identify CVD high-risk patients with 
CKD needs to be evaluated in future studies (75).
D: Neutrophil Gelatinase-Associated 
Lipocalin (NGAL)
Although acute kidney injury (AKI) and CKD are conditions 
that substantially increase morbidity and mortality, the both 
diagnosis is still made with surrogate markers of GFR, such as 
SCr, urine output, and creatinine based estimating equations. 
The creatinine-base equations are an unreliable indicator during 
acute and chronic changes in kidney function, and new biomark-
ers should have the potential to identify earlier patients with 
AKI and CKD and in the future potentially intervene to modify 
outcomes. Among them, NGAL is considered one of excellent 
biomarkers in urine and plasma for the early prediction of AKI 
as well as CKD detection (32, 76).
NGAL in AKI/CKD
Neutrophil gelatinase-associated lipocalin (NGAL), also known 
as lipocalin-2, is a 25-kDa secretary glycoprotein and a member 
of lipocalin superfamily of proteins and has been shown to be 
induced rapidly in renal tubules in response to acute injury. 
NGAL seems to be one of the earliest kidney markers of ischemic 
or nephrotoxic injury in animal models and is detected in the 
blood and urine of humans soon after AKI. A meta-analysis 
by Haase et al. demonstrated that NGAL was an early predic-
tor of subclinical AKI, with early elevations in plasma NGAL 
levels compared to SCr (77). Moreover, in-patient mortality 
was highest in those patients with elevated NGAL levels, with 
or without elevated SCr. In a prospective observational cohort 
study of 158 patients with Stage 3 or 4 CKD, it is suggested that 
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urinary NGAL in addition to conventional established CV and 
renal risk factors may improve the prediction of progression 
to ESRD requiring renal replacement therapy (78). The role 
of NGAL has also been studied in the setting of post-cardiac 
surgery, cardiac catheterization, hemolytic uremic syndrome, 
and kidney transplantation.
NGAL in CVD
Aghel et  al. recently reported that elevated admission serum 
NGAL levels was associated with heightened risk of subsequent 
development of worsening renal function (WRF) in 91 patients 
who admitted with acute HF (79). NGAL could be useful as an 
earlier marker of impending WRF during the treatment of acute 
HF. In patients with chronic HF, Damman et al. suggested that 
renal impairment is not only characterized by decreased eGFR 
and increased urinary albumin excretion but also by increased 
urinary NGAL concentration (80). Poniatowski et  al. reported 
that predictors of serum NGAL in 150 patients with chronic HF 
were NYHA class, cystatin C, and eGFR in multiple regression 
analysis (81). NGAL might be investigated as a potential early 
and sensitive marker of kidney dysfunction/injury in order to 
select the appropriate strategy for reducing the risk in the setting 
of CRS.
However, recent evidence demonstrates a diversity of expres-
sion and function of NGAL. NGAL in plasma is also generated 
by a systemic inflammation, which induces NGAL synthesis by 
extrarenal tissues and the release of NGAL from neutrophils. It 
has been implicated not only as a marker of renal function but 
also as that of neutrophil activation, a protective factor against 
apoptosis and oxidative stress. Recent reports have suggested that 
NGAL could be a biomarker of atherosclerosis or CVD as well as 
in AKI and CKD progression (82). Increased NGAL expression in 
atherosclerotic plaques has been demonstrated and serum NGAL 
levels were significantly higher in the presence of CAD and were 
correlated with the severity of the disease. Also, in HF, increased 
myocardial expression of NGAL might be one of mechanisms for 
its prognostic value, independent on the coexisting renal injury. 
A recent study by Daniels et al. showed that plasma NGAL was 
a significant predictor of mortality and CVD in community-
dwelling older adults, independent of traditional risk factors and 
kidney function, and adds incremental value to NT-proBNP and 
CRP (83).
Recently, among patients with CKD, urine levels of NGAL, 
were reported to be associated independently with future 
ischemic atherosclerotic events, but not with HF events or deaths 
(84). Higher urine NGAL may reflect a heavier burden of vascular 
diseases including subclinical inflammation and endothelial 
damage in the kidney as well as other organs. Clinical studies 
on the role of NGAL in ESRD patients are few. However, recent 
one study has showed that serum levels of NGAL in HD patients 
with CVD were significantly higher than those without CVD, and 
serum NGAL levels were independent risk factors in multivariate 
logistic regression analysis (85). Also in HD patients, increased 
serum NGAL might reflect the CV inflammation and damages. 
Further basic and clinical studies are warranted to elucidate the 
true pathogenic role of increased NGAL and to confirm the use 
as a biomarker for CRS.
e: Fibroblast Growth Factor (FGF)-23
Fibroblast growth factor-23 (FGF-23) is a recently discovered 
member of the FGF family, involved in the regulation of the body’s 
calcium-phosphate metabolism (40). It increases renal phosphate 
excretion by reducing the expression of Na/Pi IIa cotransporter 
and decreases circulating calcitriol [1,25(OH)2D3] levels, leading 
to increased parathyroid hormone levels resulting in secondary 
hyperparathyroidism. FGF-23 levels gradually increase with 
declining renal function, starting at the very earliest stages of 
CKD, increasing by many orders of magnitude in ESRD. Some 
studies suggested that most circulating FGF-23 may be function-
ally intact, indicating a mechanism involving increased FGF-23 
secretion as the cause of elevated FGF-23 levels. Oversecretion of 
FGF-23 may allow the body to maintain phosphate levels within a 
“physiological” range (~2.5–4.5 mg/dl) until very advanced CKD 
stages.
FGF-23 and Mortality
Elevated FGF-23 levels are associated with an increased risk of 
adverse outcomes, including all-cause mortality, CV events, and 
progression of CKD (86). Isakova et al. evaluated FGF-23 as a risk 
factor for adverse outcomes in a prospective 5-year study of 3,879 
participants with CKD stages 2–4. They have shown that elevated 
FGF-23 was an independent risk factor for ESRD in patients with 
relatively preserved kidney function and for mortality across the 
spectrum of CKD (41). In a nested case–control sample of 200 
subjects who died and 200 who survived during the first year 
taken from a prospective cohort of 10,044 incident HD patients, 
Gutiérrez et al. also showed that increased FGF-23 levels appear 
to be independently associated with mortality (87). Interestingly, 
some studies have described an association of FGF-23 with CV 
events and mortality in patients without CKD in whom the typi-
cal constellation of abnormal bone-mineral metabolism seen in 
CKD and ESRD is not present (88). Thus, FGF-23 may be a novel 
marker of CVD in patients with CKD and ESRD as well as in 
normal renal function, although these associations appear to be 
stronger in patients with CKD/ESRD. Also, they are independent 
of serum phosphate levels, and FGF-23 levels are a significant 
independent predictor among various parameters of calcium-
phosphate metabolism.
FGF-23 and CVD
In cross-sectional studies, increased FGF-23 levels in patients with 
CKD were found to be associated not only with therapy-resistant 
secondary hyperparathyroidism but were also independently 
related to LVH and endothelial dysfunction after adjustment 
for traditional markers of calcium–phosphate metabolism. In a 
large study of 3,939 CKD patients, Faul et al. showed that FGF-23 
was independently associated with LVH, which is an important 
mechanism of CVD in patients with CKD (89). In basic stud-
ies, this may be via the FGF receptor–dependent activation 
of the calcineurin-NFAT-signaling pathway independent of 
klotho (the co-receptor of FGF-23 only expressed in kidney and 
parathyroid glands). Treatment with an FGF receptor blocker 
is also reported to attenuate LVH. In contrast, observational 
studies reported conflicting results on the association of FGF-23 
with arterial calcification, which is another prominent pattern 
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of CV injury in CKD. In the largest study to date, FGF-23 was 
not independently associated with coronary artery calcification 
in patients with CKD stages 2–4 (90). These data suggest that 
direct effects of FGF-23 on cardiac remodeling, rather than the 
arterial vasculature, may underlie its association with mortality. 
Recently, Scialla et  al. reported that higher FGF-23 level was 
independently associated with greater risk of CV events, par-
ticularly CHF, in a prospective cohort of 3,860 participants with 
CKD stages 2–4 (91). They demonstrated that elevated FGF-23 
was associated more strongly with CHF than with atherosclerotic 
events (P = 0.02), and uniformly was associated with greater risk 
of CHF events across subgroups stratified by eGFR, proteinuria, 
prior heart disease, diabetes, BP control, anemia, LV mass index, 
and ejection fraction. Their findings suggest that FGF-23 could 
represent a novel mechanism of CHF that mediates at least a por-
tion of excess CVD risk attributable to CKD. Recently, additional 
analysis in their study showed the association of FGF-23 with 
atrial fibrillation in CKD, which is frequently observed and has 
clinical impact in patients with CKD (92). Thus, in light of the 
high CV morbidity in CKD patients, as well as the failure of 
traditional therapeutic concepts (e.g., cholesterol-lowering or 
angiotensin-converting enzyme inhibitor therapy) and of non-
traditional approaches (e.g., normalization of hemoglobin levels, 
increasing dialysis dose, and use of high-flux dialyzer), the option 
of pharmacological lowering of high circulating FGF-23 levels 
is expected to be a promising therapeutic pathway for reducing 
CVD in CKD and ESRD.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
Of great importance is recognizing the presence of CRS and 
appreciating the impact it can play on treatment options and 
survival. However, our understanding of the pathophysiology 
of CRS or CVD in CKD/ESRD remains relatively poor. Reliable 
renocardiovascular biomarkers are nowadays necessary for 
evaluating accurately the complex interactions that are the basis 
of CRS and for early diagnosis and staging of CVD and CKD/
ESRD, which lead to more accurate and efficient patient manage-
ment and the development of strategies for CV risk stratification 
and prevention in this condition. On the contrary, it is neces-
sary for clinicians and investigators to consider the pathologic 
mechanisms linking heart and kidney for the interpretation and 
utilization in such biomarkers and to look beyond just biomark-
ers measured at presentation and statistical tests of association. 
From such an integrating viewpoint, further studies into the 
biomarkers will facilitate our knowledge of CRS and improve the 
clinical managements.
Recently, the aberrant profiles of circulating microRNAs 
(miRNAs) have been evaluated as emerging biomarkers for CV 
or renal disease. For example, miR-21 is associated with organ 
fibrosis and the measurement may be useful in the detection of 
renal or myocardial fibrosis (93, 94). Several studies have started 
to clarify the prognostic roles of various miRNAs in large cohorts 
(95). However, available data are limited especially in the con-
text of CRS, and more studies and validation in large cohorts are 
necessary for establishing the clinical utility of circulating and 
urinary miRNAs. In addition, a multi-biomarker approach for 
targeting several organs or pathophysiologies is quite reasonable 
in this situation since CRS is a very complex disorder not of a 
single organ but of multi-organs including heart, vasculatures 
and kidney (52, 65). More integrated assessments of a multi-
biomarker approach will be performed and shed light on the 
clinical management in CKD and ESRD patients. Another 
advance may be in “biomarker-guided monitoring of therapy”. 
An individual patient meta-analysis suggested that BNP-guided 
monitoring of HF therapy is associated with a significant reduc-
tion in all-cause mortality in 11 studies randomizing 2,000 
patients (96). Currently, the impact of renal insufficiency on the 
treatment effect by BNP guiding remains uncertain. However, 
such trials using BNP as well as other renocardiovascular bio-
markers in CKD patients will be performed not only on HF, but 
also on CAD or LVH.
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